181 related articles for article (PubMed ID: 22459362)
21. Low prevalence of RAS-RAF-activating mutations in Spitz melanocytic nevi compared with other melanocytic lesions.
Indsto JO; Kumar S; Wang L; Crotty KA; Arbuckle SM; Mann GJ
J Cutan Pathol; 2007 Jun; 34(6):448-55. PubMed ID: 17518771
[TBL] [Abstract][Full Text] [Related]
22. NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing.
Edlundh-Rose E; Egyházi S; Omholt K; Månsson-Brahme E; Platz A; Hansson J; Lundeberg J
Melanoma Res; 2006 Dec; 16(6):471-8. PubMed ID: 17119447
[TBL] [Abstract][Full Text] [Related]
23. [MAP-Kinase pathway abnormalities in melanoma: B-RAF is not the sole cause].
Dereure O
Ann Dermatol Venereol; 2012 Oct; 139(10):691-2. PubMed ID: 23122387
[No Abstract] [Full Text] [Related]
24. [New therapies targeting the genetic mutations responsible for different types of melanoma].
Botella-Estrada R; Sanmartín Jiménez O
Actas Dermosifiliogr; 2010 Jun; 101(5):394-400. PubMed ID: 20525481
[TBL] [Abstract][Full Text] [Related]
25. Molecular characterization of human cutaneous melanoma-derived cell lines.
Ogbah Z; Puig-Butille JA; Simonetta F; Badenas C; Cervera R; Milá J; Benitez D; Malvehy J; Vilella R; Puig S
Anticancer Res; 2012 Apr; 32(4):1245-51. PubMed ID: 22493355
[TBL] [Abstract][Full Text] [Related]
26. Primary dermal melanoma: A case report and molecular characterization.
Hida Y; Kubo Y; Miyajima O; Arase S
J Dermatol; 2009 Jun; 36(6):346-52. PubMed ID: 19500183
[TBL] [Abstract][Full Text] [Related]
27. Marked genetic differences between BRAF and NRAS mutated primary melanomas as revealed by array comparative genomic hybridization.
Lázár V; Ecsedi S; Vízkeleti L; Rákosy Z; Boross G; Szappanos B; Bégány A; Emri G; Adány R; Balázs M
Melanoma Res; 2012 Jun; 22(3):202-14. PubMed ID: 22456166
[TBL] [Abstract][Full Text] [Related]
28. [Gene abnormalities in melanoma and signal transduction antagonists].
Takada M
Gan To Kagaku Ryoho; 2013 Apr; 40(4):453-7. PubMed ID: 23894754
[No Abstract] [Full Text] [Related]
29. Melanocytic lesions, Spitz tumors, and Don Ferrante's logic.
Urso C
Am J Dermatopathol; 2007 Oct; 29(5):491-4. PubMed ID: 17890925
[No Abstract] [Full Text] [Related]
30. Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis.
Lee JH; Choi JW; Kim YS
Br J Dermatol; 2011 Apr; 164(4):776-84. PubMed ID: 21166657
[TBL] [Abstract][Full Text] [Related]
31. BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma.
Colombino M; Capone M; Lissia A; Cossu A; Rubino C; De Giorgi V; Massi D; Fonsatti E; Staibano S; Nappi O; Pagani E; Casula M; Manca A; Sini M; Franco R; Botti G; Caracò C; Mozzillo N; Ascierto PA; Palmieri G
J Clin Oncol; 2012 Jul; 30(20):2522-9. PubMed ID: 22614978
[TBL] [Abstract][Full Text] [Related]
32. B-raf exon 15 mutations are common in primary melanoma resection specimens but not associated with clinical outcome.
Deichmann M; Thome M; Benner A; Näher H
Oncology; 2004; 66(5):411-9. PubMed ID: 15331929
[TBL] [Abstract][Full Text] [Related]
33. Genetic diversity in melanoma.
Meltzer PS
N Engl J Med; 2005 Nov; 353(20):2104-7. PubMed ID: 16291979
[No Abstract] [Full Text] [Related]
34. Targeting NRAS in melanoma.
Kelleher FC; McArthur GA
Cancer J; 2012; 18(2):132-6. PubMed ID: 22453013
[TBL] [Abstract][Full Text] [Related]
35. Differences in global gene expression in melanoma cell lines with and without homozygous deletion of the CDKN2A locus genes.
Bloethner S; Hemminki K; Thirumaran RK; Chen B; Mueller-Berghaus J; Ugurel S; Schadendorf D; Kumar R
Melanoma Res; 2006 Aug; 16(4):297-307. PubMed ID: 16845325
[TBL] [Abstract][Full Text] [Related]
36. Absence of BRAF gene mutations differentiates spitz nevi from malignant melanoma.
Mihic-Probst D; Perren A; Schmid S; Saremaslani P; Komminoth P; Heitz PU
Anticancer Res; 2004; 24(4):2415-8. PubMed ID: 15330192
[TBL] [Abstract][Full Text] [Related]
37. Re: Determinants of BRAF mutations in primary melanomas.
Purdue MP
J Natl Cancer Inst; 2005 Mar; 97(5):401-2; author reply 402. PubMed ID: 15741578
[No Abstract] [Full Text] [Related]
38. The oncogenic B-raf V599E mutation occurs more frequently in melanomas at sun-protected body sites.
Deichmann M; Krahl D; Thome M; Wüst K; Hassanzadeh J; Helmke B
Int J Oncol; 2006 Jul; 29(1):139-45. PubMed ID: 16773193
[TBL] [Abstract][Full Text] [Related]
39. Management of familial melanoma and nonmelanoma skin cancer syndromes.
Santillan AA; Cherpelis BS; Glass LF; Sondak VK
Surg Oncol Clin N Am; 2009 Jan; 18(1):73-98, viii. PubMed ID: 19056043
[TBL] [Abstract][Full Text] [Related]
40. Signalling and chemosensitivity assays in melanoma: is mutated status a prerequisite for targeted therapy?
Passeron T; Lacour JP; Allegra M; Ségalen C; Deville A; Thyss A; Giacchero D; Ortonne JP; Bertolotto C; Ballotti R; Bahadoran P
Exp Dermatol; 2011 Dec; 20(12):1030-2. PubMed ID: 22092579
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
